Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma

M. R. Sertoli, I. Brunetti, A. Ardizzoni, A. Falcone, D. Guarneri, F. Boccardo, G. Martorana, A. Curotto, A. Sicignano, R. Rosso, L. Santi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant α-2a interferon (18 x 106 U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10% response rate; 95% confidence limits 1.23-31.7%) achieved partial response and 11 (55%) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant α-2a interferon and vinblastine is active in renal cell carcinoma.

Original languageEnglish
Pages (from-to)43-45
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume12
Issue number1
Publication statusPublished - 1989

Fingerprint

Vinblastine
Renal Cell Carcinoma
Interferons
Therapeutics
Anorexia
Fatigue
Fever

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. / Sertoli, M. R.; Brunetti, I.; Ardizzoni, A.; Falcone, A.; Guarneri, D.; Boccardo, F.; Martorana, G.; Curotto, A.; Sicignano, A.; Rosso, R.; Santi, L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 12, No. 1, 1989, p. 43-45.

Research output: Contribution to journalArticle

Sertoli, MR, Brunetti, I, Ardizzoni, A, Falcone, A, Guarneri, D, Boccardo, F, Martorana, G, Curotto, A, Sicignano, A, Rosso, R & Santi, L 1989, 'Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 12, no. 1, pp. 43-45.
Sertoli, M. R. ; Brunetti, I. ; Ardizzoni, A. ; Falcone, A. ; Guarneri, D. ; Boccardo, F. ; Martorana, G. ; Curotto, A. ; Sicignano, A. ; Rosso, R. ; Santi, L. / Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1989 ; Vol. 12, No. 1. pp. 43-45.
@article{1731b3632e6d436b9e88626f7e946fe6,
title = "Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma",
abstract = "Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant α-2a interferon (18 x 106 U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10{\%} response rate; 95{\%} confidence limits 1.23-31.7{\%}) achieved partial response and 11 (55{\%}) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant α-2a interferon and vinblastine is active in renal cell carcinoma.",
author = "Sertoli, {M. R.} and I. Brunetti and A. Ardizzoni and A. Falcone and D. Guarneri and F. Boccardo and G. Martorana and A. Curotto and A. Sicignano and R. Rosso and L. Santi",
year = "1989",
language = "English",
volume = "12",
pages = "43--45",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Recombinant α-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma

AU - Sertoli, M. R.

AU - Brunetti, I.

AU - Ardizzoni, A.

AU - Falcone, A.

AU - Guarneri, D.

AU - Boccardo, F.

AU - Martorana, G.

AU - Curotto, A.

AU - Sicignano, A.

AU - Rosso, R.

AU - Santi, L.

PY - 1989

Y1 - 1989

N2 - Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant α-2a interferon (18 x 106 U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10% response rate; 95% confidence limits 1.23-31.7%) achieved partial response and 11 (55%) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant α-2a interferon and vinblastine is active in renal cell carcinoma.

AB - Twenty consecutive metastatic renal cell carcinoma patients were treated with a combination of recombinant α-2a interferon (18 x 106 U three times weekly) and vinblastine (0.1 mg/kg every 3 weeks). Two patients (10% response rate; 95% confidence limits 1.23-31.7%) achieved partial response and 11 (55%) stable disease. Toxicity was significant but always acceptable: most frequently, patients complained of fever and flu-like symptoms (18 of 19 patients), fatigue (18 of 19 patients), worsening in performance status (15 of 19 patients), and anorexia (15 of 19). The combination of recombinant α-2a interferon and vinblastine is active in renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0024552005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024552005&partnerID=8YFLogxK

M3 - Article

C2 - 2492141

AN - SCOPUS:0024552005

VL - 12

SP - 43

EP - 45

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -